arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

FENNEC PHARMACEUTICALS INC.

FENC
$11.58 ▲ +0.72 (+6.63%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
117 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

FENNEC PHARMACEUTICALS INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $397.6M
Dividend Yield
Revenue Growth 72.6%
Op. Margin -0.8%
ROIC -0.2%
FCF / Share $0.07
Trailing P/E 1158.0x
Price / Book 10.6x
FCF Yield 0.6%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

117-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$15.11M
↑ +72.6%
Net Income Profit after all expenses
$201.00K
↑ +104.2%
Operating Margin Operating profit as % of sales
-0.8%
↑ +95.8% 12th
FCF / Share Free cash flow per share
$0.07
↑ +29.4%
Long-Term Debt Long-term obligations
$19.38M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
24
Financial Health
40
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 30 years · 117 quarters